AnHeart Therapeutics has entered into an exclusive license agreement with Nippon Kayaku Co., Ltd to market and distribute AnHeart’s lead investigational therapy, taletrectinib, in Japan.
FDA has granted accelerated approval to sevabertinib (Hyrnuo), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-authorized test.
